Compare ALEMBIC PHARMA with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs FULFORD INDIA - Comparison Results

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA FULFORD INDIA ALEMBIC PHARMA/
FULFORD INDIA
 
P/E (TTM) x 16.6 398.8 4.2% View Chart
P/BV x 6.6 6.2 106.0% View Chart
Dividend Yield % 0.6 0.1 683.8%  

Financials

 ALEMBIC PHARMA   FULFORD INDIA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
FULFORD INDIA
Mar-14
ALEMBIC PHARMA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs664942 70.5%   
Low Rs412450 91.6%   
Sales per share (Unadj.) Rs208.7691.4 30.2%  
Earnings per share (Unadj.) Rs31.011.5 270.5%  
Cash flow per share (Unadj.) Rs37.115.4 241.6%  
Dividends per share (Unadj.) Rs5.502.00 275.0%  
Dividend yield (eoy) %1.00.3 355.6%  
Book value per share (Unadj.) Rs144.2380.0 38.0%  
Shares outstanding (eoy) m188.523.90 4,833.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.61.0 256.2%   
Avg P/E ratio x17.460.7 28.6%  
P/CF ratio (eoy) x14.545.3 32.0%  
Price / Book Value ratio x3.71.8 203.7%  
Dividend payout %17.717.4 101.7%   
Avg Mkt Cap Rs m101,4612,714 3,737.9%   
No. of employees `000NA0.4 0.0%   
Total wages/salary Rs m7,467505 1,478.6%   
Avg. sales/employee Rs ThNM6,073.0-  
Avg. wages/employee Rs ThNM1,137.4-  
Avg. net profit/employee Rs ThNM100.7-  
INCOME DATA
Net Sales Rs m39,3472,696 1,459.2%  
Other income Rs m94125 74.8%   
Total revenues Rs m39,4412,822 1,397.7%   
Gross profit Rs m8,736-46 -18,827.2%  
Depreciation Rs m1,15215 7,580.9%   
Interest Rs m18410 1,937.9%   
Profit before tax Rs m7,49354 13,799.6%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,56810 16,328.1%   
Profit after tax Rs m5,84445 13,073.2%  
Gross profit margin %22.2-1.7 -1,290.2%  
Effective tax rate %20.917.7 118.3%   
Net profit margin %14.91.7 895.9%  
BALANCE SHEET DATA
Current assets Rs m19,5771,738 1,126.2%   
Current liabilities Rs m14,896545 2,734.8%   
Net working cap to sales %11.944.3 26.9%  
Current ratio x1.33.2 41.2%  
Inventory Days Days9048 185.2%  
Debtors Days Days454 1,053.6%  
Net fixed assets Rs m27,09712 227,704.2%   
Share capital Rs m37739 966.7%   
"Free" reserves Rs m26,8111,443 1,858.0%   
Net worth Rs m27,1881,482 1,834.6%   
Long term debt Rs m4,9930-   
Total assets Rs m47,7782,077 2,300.7%  
Interest coverage x41.76.7 621.0%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.81.3 63.4%   
Return on assets %12.62.6 483.4%  
Return on equity %21.53.0 712.6%  
Return on capital %23.64.3 548.2%  
Exports to sales %00-   
Imports to sales %024.5 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA659 0.0%   
Fx inflow Rs m19,45317 113,097.1%   
Fx outflow Rs m6,065673 900.9%   
Net fx Rs m13,388-656 -2,041.0%   
CASH FLOW
From Operations Rs m8,12090 9,021.8%  
From Investments Rs m-7,556105 -7,223.7%  
From Financial Activity Rs m590-14 -4,187.2%  
Net Cashflow Rs m1,153181 638.9%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 2.9 3.8 76.3%  
FIIs % 9.1 0.1 9,100.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 21.2 65.6%  
Shareholders   49,328 4,783 1,031.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   BIOCON   CADILA HEALTHCARE  VENUS REMEDIES  DR. DATSONS LABS  WOCKHARDT  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

SGX Nifty Up 126 Points; Indicates Gap-Up Opening for Indian Stock Markets(SGX Nifty)

The SGX Nifty opened on a positive note today. At 8:10 am, it was trading up by 126 points, or 0.87% higher at 14,480 levels.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 13.8% (Quarterly Result Update)

Jan 19, 2021 | Updated on Jan 19, 2021

For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 33.3% (Quarterly Result Update)

Jan 23, 2020 | Updated on Jan 23, 2020

For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 25.2% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

Buzzing Sectors Before Budget 2021(Fast Profits Daily)

Jan 12, 2021

The budget is just a few weeks away. Which stocks can you expect to move? Find out in this video.

Here's Why Smallcaps Could Be Your Best Investment in 2021(Profit Hunter)

Jan 12, 2021

Select smallcaps hold a great potential to become the multibaggers of tomorrow. Here's how you could get in early into these stocks.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jan 25, 2021 09:24 AM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS